[Fosun Pharma: New indications for Ruwometinib tablets approved by the State Food and Drug Administration] On September 3, Fosun Pharma (600196.SH) announced that the company’s controlled subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.’s drug registration application for new indications for Ruwometinib Tablets was approved by the State Food and Drug Administration. The new indication approved this time is for adult patients with type I neurofibromatosis associated with symptomatic, inoperable plexiform neurofibromas. As of the date of the announcement, three other indications of the drug have been approved for marketing in China, and many indications are in the clinical trial stage. As of July 2026, the cumulative R&D investment is approximately 714 million yuan.